+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Chronic Obstructive Pulmonary Disease Drug"

From
From
From
From
From
From
From
From
From
From
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2020 - Product Thumbnail Image

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2020

  • Drug Pipelines
  • October 2020
  • 576 Pages
  • Global
From
Formaldehyde Dehydrogenase - Pipeline Review, H2 2019 - Product Thumbnail Image

Formaldehyde Dehydrogenase - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 27 Pages
  • Global
From
Loading Indicator

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that affects millions of people worldwide. It is characterized by difficulty breathing, coughing, and wheezing. COPD is typically treated with a combination of medications, including bronchodilators, inhaled corticosteroids, and antibiotics. The COPD drug market is a subset of the larger respiratory drug market, which includes drugs used to treat asthma, allergies, and other respiratory conditions. The COPD drug market is highly competitive, with a variety of companies offering different types of medications. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis, and Merck. These companies offer a range of COPD medications, including bronchodilators, inhaled corticosteroids, and antibiotics. Other companies, such as Teva Pharmaceuticals and Mylan, also offer generic versions of these medications. Show Less Read more